Details

Autor(en) / Beteiligte

• Heudel, P.
• Chabaud, S.
• Perol, D.
• Flechon, A.
• Fayette, J.
• Combemale, P.
• Tredan, O.
• Desseigne, F.
• de la Fouchardiere, C.
• Boyle, H.
• Perol, M.
• Bachelot, T.
• Cassier, P.
• Avrillon, V.
• Terret, C.
• Michallet, A.-S.
• Neidhardt-Berard, E.-M.
• Nicolas-Virelizier, E.
• Dufresne, A.
• Belhabri, A.
• Brahmi, M.
• Lebras, L.
• Nicolini, F.
• Sarabi, M.
• Rey, P.
• Bonneville-Levard, A.
• Rochefort, P.
• Provensal, A.-M.
• Eberst, L.
• Assaad, S.
• Swalduz, A.
• Saintigny, P.
• Toussaint, P.
• Guillermin, Y.
• Castets, M.
• Coutzac, C.
• Meeus, P.
• Dupré, A.
• Durand, T.
• Crochet, H.
• Fervers, B.
• Gomez, F.
• Rivoire, M.
• Gregoire, V.
• Claude, L.
• Chassagne-Clement, C.
• Pilleul, F.
• Mognetti, T.
• Russias, B.
• Soubirou, J.-L.
• Lasset, C.
• Chvetzoff, G.
• Mehlen, P.
• Beaupère, S.
• Zrounba, P.
• Ray-Coquard, I.
• Blay, J.-Y.

Titel

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Ist Teil von

• ESMO open, 2021-02, Vol.6 (1), p.100044-100044, Article 100044

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2021

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Second primary cancers (SPCs) are diagnosed in over 5% of patients after a first primary cancer (FPC). We explore here the impact of immune checkpoint inhibitors (ICIs) given for an FPC on the risk of SPC in different age groups, cancer types and treatments. The files of the 46 829 patients diagnosed with an FPC in the Centre Léon Bérard from 2013 to 2018 were analyzed. Structured data were extracted and electronic patient records were screened using a natural language processing tool, with validation using manual screening of 2818 files of patients. Univariate and multivariate analyses of the incidence of SPC according to patient characteristics and treatment were conducted. Among the 46 829 patients, 1830 (3.9%) had a diagnosis of SPC with a median interval of 11.1 months (range 0-78 months); 18 128 (38.7%) received cytotoxic chemotherapy (CC) and 1163 (2.5%) received ICIs for the treatment of the FPC in this period. SPCs were observed in 7/1163 (0.6%) patients who had received ICIs for their FPC versus 437/16 997 (2.6%) patients receiving CC and no ICIs for the FPC versus 1386/28 669 (4.8%) for patients receiving neither CC nor ICIs for the FPC. This reduction was observed at all ages and for all histotypes analyzed. Treatment with ICIs and/or CC for the FPC are associated with a reduced risk of SPC in multivariate analysis. Immunotherapy with ICIs alone and in combination with CC was found to be associated with a reduced incidence of SPC for all ages and cancer types. •From 2013 to 2018, 3.9% of the 46 829 patients diagnosed with a first cancer presented with an SPC.•Treatment of the first cancer with ICIs was associated with a major reduction of SPC.•CC given for an FPC was also associated with a lower magnitude of reduction of SPC.•There were no SPC in cancer patients treated with ICIs in the localized phase of their first cancer.